Lymphoma News

Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free lymphoma classification, results showed.

Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19, study results showed.

Mosunetuzumab more than quadrupled the complete response rate among patients with relapsed or refractory follicular lymphoma, according to results of a pivotal phase 2 study.

Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody response, according to results of a prospective, observational single-center study presented at ASH Annual Meeting and Exposition.

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

The William L. McGuire Lecture Award will be presented to Olufunmilayo Olopade, MD, FAACR, at San Antonio Breast Cancer Symposium this month.